Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-T cells (Mingzhi Zhang)
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Zhengzhou University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CAR-T cells (Mingzhi Zhang) refers to a clinical research program and suite of autologous chimeric antigen receptor T-cell therapies developed and investigated by Professor Mingzhi Zhang at the First Affiliated Hospital of Zhengzhou University. This program evaluates various CAR-T constructs targeting specific tumor-associated antigens, including CD19, CD20, and CD22 for B-cell malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphomas, as well as B-cell maturation antigen (BCMA) for multiple myeloma. The therapy involves the genetic modification of a patient's own T cells to express a CAR that recognizes these specific surface proteins, enabling the immune system to identify and destroy malignant cells. These therapies are primarily being evaluated in patients with relapsed or refractory (R/R) hematological and lymphatic tumors.
- Other names
- CAR-T cells (Zhengzhou University)Anti-CD19 CAR-T cellsAnti-CD-19 CAR-T cellsAnti-CD 19 CAR-T cellsAnti-CD20 CAR-T cellsAnti-CD-20 CAR-T cellsAnti-CD 20 CAR-T cellsAnti-CD22 CAR-T cellsAnti-CD-22 CAR-T cellsAnti-CD 22 CAR-T cellsAnti-BCMA CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CAR-T cells (Mingzhi Zhang).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-T cells (Mingzhi Zhang).